Skin Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SKN015 MIFTS: 67	Skin Carcinoma Categories: Cancer diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Skin Carcinoma

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma ¹¹ ⁵³ ¹⁴ ¹⁶

Skin Cancer ¹¹ ¹⁹ ⁵³ ⁴¹ ² ¹⁴ ⁷⁵

Melanoma and Non-Melanoma Skin Cancer ¹¹

Malignant Neoplasm of Skin ¹¹

Carcinoma of Skin ¹¹

Ca - Skin Cancer ¹¹

Cancer of Skin ¹¹

Skin Cancers ¹⁴

Cancer, Skin ³⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3451 DOID:4159

MeSH ⁴³ D012878

NCIt ⁴⁹ C2920 C4914

SNOMED-CT ⁶⁸ 94047004

EFO ¹⁶ EFO_0009259

UMLS ⁷¹ C0007114 C0699893

Sources

Summaries for Skin Carcinoma

MedlinePlus: ⁴¹ Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who : Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary: Skin Carcinoma, also known as skin cancer, is related to xeroderma pigmentosum, complementation group f and rothmund-thomson syndrome, type 2. An important gene associated with Skin Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Homology Directed Repair and Transcription-Coupled Nucleotide Excision Repair (TC-NER). The drugs Petrolatum and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include tissues of the skin, skin and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Increased TP53 mRNA expression

CDC: ² Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer-basal cell and squamous cell carcinomas-are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of cases of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

GARD: ¹⁹ A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas.

Disease Ontology ¹¹ Skin carcinoma: A skin cancer that is located in tissues of the skin and develops from epithelial cells.

Skin cancer: An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

Wikipedia: ⁷⁵ Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells... more...

Sources

Related Diseases for Skin Carcinoma

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 961)

#	Related Disease	Score	Top Affiliating Genes
1	xeroderma pigmentosum, complementation group f	32.6	XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
2	rothmund-thomson syndrome, type 2	32.5	H2AC18 ERCC6 ERCC3 ERCC2
3	xeroderma pigmentosum, complementation group c	32.4	XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
4	acral lentiginous melanoma	32.4	TYR MC1R CDK4
5	xeroderma pigmentosum, complementation group a	32.3	XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
6	penis carcinoma in situ	32.3	TP53 PTCH1
7	basal cell nevus syndrome	32.3	TP53 PTCH1 MC1R
8	xeroderma pigmentosum, complementation group g	32.3	XPA POLH H2AC18 ERCC6 ERCC3 ERCC2
9	cockayne syndrome a	32.3	XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
10	epidermodysplasia verruciformis 1	32.2	TP53 TMC8 TMC6
11	xeroderma pigmentosum, complementation group d	32.2	XPA ERCC3 ERCC2
12	basal cell carcinoma	32.1	XPA TYR TP53 PTCH1 MC1R ICOSLG
13	trichothiodystrophy	32.1	XPA TP53 POLH H2AC18 ERCC6 ERCC3
14	cockayne syndrome b	32.1	XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
15	cowden syndrome	32.0	TP53 PTCH1 MIR21 ERCC6
16	prostate cancer	31.9	TYR TP53 PTGS2 MIR21 JUN H2AC18
17	albinism, oculocutaneous, type ia	31.5	TYR MC1R
18	lymphoma, hodgkin, classic	31.4	TP53 MIR21 ICOSLG H2AC18 CCR6
19	vitiligo-associated multiple autoimmune disease susceptibility 1	31.4	TYR MC1R ICOSLG CCR6
20	melanoma in congenital melanocytic nevus	31.2	TYR TP53 MIR21 MC1R H2AC18 CDK4
21	telangiectasis	31.1	TP53 H2AC18 ERCC6 CCR6
22	viral infectious disease	31.1	MIR21 ICOSLG H2AC18 CCR6
23	head and neck cancer	31.0	TP53 MIR21 ICOSLG H2AC18 ERCC6 CCR6
24	basosquamous carcinoma	31.0	TP53 PTCH1
25	lymphoma, non-hodgkin, familial	31.0	TP53 MIR21 ICOSLG H2AC18 CCR6 CASP3
26	primary cutaneous t-cell non-hodgkin lymphoma	31.0	MIR21 H2AC18 CCR6
27	skin benign neoplasm	31.0	XPA TYR TP53 PTCH1 JUN ERCC3
28	cockayne syndrome	30.9	XPA TP53 JUN ERCC6 ERCC3 ERCC2
29	systemic scleroderma	30.8	MIR21 ICOSLG H2AC18 CCR6
30	actinic keratosis	30.8	XPA TP53 TMC8 PTGS2 MC1R H2AC18
31	melanoma, cutaneous malignant 1	30.8	TYR TP53 MC1R ERCC2 CDK4
32	melanoma	30.8	TYR TP53 MIR21 MC1R JUN DDB2
33	nodular malignant melanoma	30.8	TYR TP53 MC1R CDK4
34	anogenital venereal wart	30.8	TP53 TMC8 H2AC18 CCR6
35	ataxia-telangiectasia	30.8	XPA TP53 JUN ERCC3 CASP3
36	exanthem	30.8	ICOSLG H2AC18 CCR6
37	adult t-cell leukemia/lymphoma	30.8	TP53 ICOSLG H2AC18 CCR6
38	t-cell acute lymphoblastic leukemia	30.7	JUN ICOSLG H2AC18 CDK4 CCR6 CASP3
39	squamous cell carcinoma, head and neck	30.7	TP53 PTGS2 MIR21 JUN ICOSLG H2AC18
40	kidney cancer	30.7	TP53 MIR21 ICOSLG H2AC18 CCR6
41	allergic disease	30.7	MIR21 ICOSLG H2AC18 CCR6
42	papilloma	30.7	TP53 PTGS2 CCR6 CASP3
43	myelodysplastic syndrome	30.7	TP53 ICOSLG H2AC18 CDK4 CCR6 CASP3
44	li-fraumeni syndrome	30.6	TP53 PTCH1 H2AC18 CDK4
45	contact dermatitis	30.6	MIR21 ICOSLG CCR6
46	crohn's disease	30.6	MIR21 ICOSLG H2AC18 CCR6
47	deficiency anemia	30.6	TP53 ICOSLG H2AC18 ERCC6 CCR6
48	skin melanoma	30.6	TYR TP53 MIR21 MC1R ICOSLG H2AC18
49	common wart	30.6	TP53 TMC8 TMC6
50	body mass index quantitative trait locus 11	30.6	TP53 PTGS2 MIR21 MC1R JUN ICOSLG

Graphical network of the top 20 diseases related to Skin Carcinoma:

Sources

Symptoms & Phenotypes for Skin Carcinoma

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.8	DDB2 ERCC6 JUN
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.8	DDB2 ERCC6 JUN TP53
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.8	DDB2 ERCC2 ERCC3 ERCC6 JUN POLH
4	Increased TP53 mRNA expression	GR00389-S-5	8.32	JUN

MGI Mouse Phenotypes related to Skin Carcinoma:

⁴⁵ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.39	CASP3 CCR6 CDK4 ERCC2 ERCC3 ERCC6
2	growth/size/body region	MP:0005378	10.38	CASP3 CDK4 DDB2 ERCC2 ERCC3 ERCC6
3	neoplasm	MP:0002006	10.34	CDK4 DDB2 ERCC2 ERCC3 ERCC6 MC1R
4	nervous system	MP:0003631	10.31	CASP3 CCR6 CDK4 ERCC2 ERCC3 ERCC6
5	immune system	MP:0005387	10.24	CASP3 CCR6 CDK4 ERCC2 ERCC6 ICOSLG
6	pigmentation	MP:0001186	10.22	CASP3 CDK4 ERCC2 MC1R POLH PTCH1
7	cellular	MP:0005384	10.22	CASP3 CDK4 DDB2 ERCC2 ERCC3 ERCC6
8	endocrine/exocrine gland	MP:0005379	10.16	CASP3 CDK4 ERCC2 ERCC3 JUN PTCH1
9	muscle	MP:0005369	10.13	CASP3 CDK4 ERCC3 ERCC6 PTCH1 PTGS2
10	craniofacial	MP:0005382	10.13	CASP3 CDK4 ERCC3 JUN MC1R POLH
11	no phenotypic analysis	MP:0003012	10.09	CASP3 JUN MC1R PTCH1 PTGS2 TP53
12	reproductive system	MP:0005389	10.06	CASP3 CDK4 ERCC2 ERCC3 PTCH1 PTGS2
13	hearing/vestibular/ear	MP:0005377	10.04	CASP3 ERCC6 MC1R POLH PTCH1 TP53
14	skeleton	MP:0005390	10.03	CASP3 CDK4 ERCC2 ERCC3 ERCC6 JUN
15	vision/eye	MP:0005391	9.85	CASP3 CDK4 ERCC2 ERCC6 JUN PTCH1
16	hematopoietic system	MP:0005397	9.83	CASP3 CCR6 CDK4 ERCC2 ERCC3 ERCC6
17	integument	MP:0010771	9.53	CASP3 CDK4 DDB2 ERCC2 ERCC3 ERCC6

Sources

Drugs & Therapeutics for Skin Carcinoma

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Petrolatum

Approved, Investigational

Phase 4

8009-03-8

Etanercept

Approved, Investigational

Phase 4

185243-69-0

Bacitracin

Approved, Vet_approved

Phase 4

1405-87-4

10909430

Erythromycin

Approved, Investigational, Vet_approved

Phase 4

114-07-8

12560

Mineral oil

Approved, Vet_approved

Phase 4

8042-47-5

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Azathioprine

Approved

Phase 4

446-86-6

2265

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

Mycophenolic acid

Approved, Investigational

Phase 4

24280-93-1

446541

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Dermatologic Agents

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Anti-Inflammatory Agents

Phase 4

Gastrointestinal Agents

Phase 4

Erythromycin stearate

Phase 4

Erythromycin Ethylsuccinate

Phase 4

Erythromycin Estolate

Phase 4

Polymyxins

Phase 4

Lubricant Eye Drops

Phase 4

Calcineurin Inhibitors

Phase 4

Cyclosporins

Phase 4

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Antifungal Agents

Phase 4

Antimetabolites

Phase 4

Antibiotics, Antitubercular

Phase 4

Neurotransmitter Agents

Phase 4

Agglutinins

Phase 4

abobotulinumtoxinA

Phase 4

Botulinum Toxins, Type A

Phase 4

Botulinum Toxins

Phase 4

Hemagglutinins

Phase 4

Cholinergic Agents

Phase 4

Everolimus

Approved

Phase 3

159351-69-6

70789204 6442177

Aminolevulinic acid

Approved

Phase 3

106-60-5

137

Eflornithine

Approved, Withdrawn

Phase 3

70052-12-9

3009

Acetaminophen

Approved

Phase 3

103-90-2

1983

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Dacarbazine

Approved, Investigational

Phase 3

4342-03-4

2942 5351166

Ornithine

Approved, Nutraceutical

Phase 3

3184-13-2, 70-26-8

6262

Linrodostat

Investigational

Phase 3

1923833-60-6

121328278

Radiation-Protective Agents

Phase 2, Phase 3

Sunscreening Agents

Phase 2, Phase 3

Protective Agents

Phase 2, Phase 3

Photosensitizing Agents

Phase 3

Antiprotozoal Agents

Phase 3

Antiparasitic Agents

Phase 3

Interventional clinical trials:

(show top 50) (show all 385)

#	Name	Status	NCT ID	Phase	Drugs
1	Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients	Completed	NCT00492895	Phase 4	Discontinuation of Azathioprin
2	Can We Miss Pigmented Lesions in Psoriasis Patients?	Completed	NCT01053819	Phase 4	etanercept
3	The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery	Completed	NCT03199911	Phase 4	Topical Antibiotic Product;Topical Non-Antibiotic Ointment
4	A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen	Completed	NCT00129961	Phase 4	sirolimus;cyclosporine or tacrolimus
5	Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol	Terminated	NCT00866684	Phase 4	Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
6	Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol	Terminated	NCT01797315	Phase 4	Sirolimus
7	A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer	Terminated	NCT01459666	Phase 4	Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
8	CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial	Unknown status	NCT00799188	Phase 3	Everolimus
9	A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated	Completed	NCT03329846	Phase 3	BMS-986205;Placebo
10	Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors	Completed	NCT00133887	Phase 3	rapamycin;ciclosporine;tacrolimus
11	A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma	Completed	NCT00066872	Phase 3	imiquimod
12	Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial	Completed	NCT00005884	Phase 3	eflornithine
13	Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers	Completed	NCT03131713	Phase 3	Acetaminophen
14	A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients	Completed	NCT00021125	Phase 3
15	Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00193895	Phase 3	Carboplatin
16	Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery	Completed	NCT00367042	Phase 2, Phase 3
17	Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2	Completed	NCT00002882	Phase 3	Cisplatin;Dacarbazine;Vinblastine
18	A Randomized Control Trial of Sun Protection Interventions for Operating Engineers	Completed	NCT01804595	Phase 2, Phase 3
19	Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial	Completed	NCT04549675	Phase 3
20	A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer	Completed	NCT00472459	Phase 3
21	A Personalized Approach to Skin Cancer Prevention Among Adolescents	Recruiting	NCT04341064	Phase 3
22	Risk Information and Skin-Cancer Education and Undergraduate Prevention Trial	Not yet recruiting	NCT05634252	Phase 3
23	Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma	Unknown status	NCT00747903	Phase 2	aminolevulinic acid hydrochloride
24	A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin	Unknown status	NCT00423397	Phase 1, Phase 2	gefitinib
25	Skin Cancer Prophylaxis by Low-Fat Dietary Intervention	Unknown status	NCT00003097	Phase 2
26	Transient Infrared Imaging for Early Detection of Skin Cancer	Unknown status	NCT02154451	Phase 1, Phase 2
27	A Phase 2 Study of SBRT for Squamous Cell Carcinoma of the Head and Neck	Unknown status	NCT04435938	Phase 2
28	Investigation of a Behavioral Substitute for Sunbathing	Completed	NCT00403377	Phase 1, Phase 2
29	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma	Completed	NCT00804908	Phase 2	temozolomide;ABT-888
30	Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours	Completed	NCT01861496	Phase 1, Phase 2	LiPlaCis
31	Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes	Completed	NCT00509288	Phase 2	Cyclophosphamide;Fludarabine
32	Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma	Completed	NCT00520299	Phase 1, Phase 2	ADI PEG 20
33	A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck	Completed	NCT01835626	Phase 2	Vismodegib
34	Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin	Completed	NCT00665470	Phase 2	Aldesleukin
35	Study of Talabostat and Cisplatin in Advanced Melanoma	Completed	NCT00083252	Phase 2	talabostat (PT-100) tablets;cisplatin
36	Study of Talabostat in Advanced Melanoma	Completed	NCT00083239	Phase 2	talabostat (PT-100) tablets
37	A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin	Completed	NCT00054691	Phase 2	Iressa
38	Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy	Completed	NCT00002963	Phase 2	aminolevulinic acid hydrochloride
39	Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas	Completed	NCT01108094	Phase 2	Itraconazole
40	Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms	Completed	NCT00021294	Phase 2	eflornithine;triamcinolone
41	A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00006361	Phase 2	semaxanib
42	A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia	Completed	NCT00563290	Phase 2	dasatinib
43	A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer	Completed	NCT00089180	Phase 2	liposomal T4N5 lotion
44	A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses	Completed	NCT00002975	Phase 2	aminolevulinic acid
45	ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS	Completed	NCT00002506	Phase 2	isotretinoin
46	Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines	Completed	NCT00923195	Phase 2	MART-1: 26-35(27L) Peptide;Montanide ISA 51 VG;gp100:154-162 Peptide;Aldesleukin;Fludarabine;Cyclophosphamide
47	A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome	Completed	NCT00023621	Phase 2	celecoxib
48	Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma	Completed	NCT00295958	Phase 2
49	Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma	Completed	NCT00885534	Phase 2	Cisplatin, Vinblastine, Temozolomide
50	A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin	Completed	NCT00126555	Phase 2	Gefitinib

Search NIH Clinical Center for Skin Carcinoma

Sources

Genetic Tests for Skin Carcinoma

Sources

Anatomical Context for Skin Carcinoma

Organs/tissues related to Skin Carcinoma:

FMA: Tissues Of The Skin, Skin

MalaCards : Skin, Lymph Node, Breast, Lung, Liver, Kidney, Heart

Sources

Publications for Skin Carcinoma

Articles related to Skin Carcinoma:

(show top 50) (show all 26358)

#	Title	Authors	PMID	Year
1	Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. ⁴¹	Nguyen JH...Al-Huniti N	36251220	2022
2	Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. ⁴¹	Larkin J...Mandala M	35964471	2022
3	Describing, predicting and explaining adherence to total skin self-examination (TSSE) in people with melanoma: a 12-month longitudinal study. ⁴¹	Allan JL...Murchie P	36041758	2022
4	Signaling pathways in melanosome biogenesis and pathology. ⁵³ ⁶²	Schiaffino MV	20381640	2010
5	Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. ⁵³ ⁶²	Kim JE...Lee HJ	20096264	2010
6	TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. ⁵³ ⁶²	Rasanen K...Vaheri A	20399617	2010
7	Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. ⁵³ ⁶²	Perrett CM...Karran P	19818066	2010
8	Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. ⁵³ ⁶²	Kane EV...Lightfoot T	20129839	2010
9	Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation. ⁵³ ⁶²	Jung YS...Chen X	20008555	2010
10	The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. ⁵³ ⁶²	Loser K...Luger TA	20126537	2010
11	Predictive testing of the melanocortin 1 receptor for skin cancer and photoaging. ⁵³ ⁶²	Lynde CW...Sapra S	20066389	2010
12	Mutagenesis: mutating a gene while reading it. ⁵³ ⁶²	Helleday T	20129038	2010
13	MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. ⁵³ ⁶²	Boyd S...Saarialho-Kere U	19601983	2009
14	The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. ⁵³ ⁶²	Kostner K...Reichrath J	19667145	2009
15	Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. ⁵³ ⁶²	Gao YJ...Ji RR	19445931	2009
16	Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. ⁵³ ⁶²	Sanchez-Laorden BL...Garcia-Borron JC	19452503	2009
17	Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. ⁵³ ⁶²	Nan H...Han J	19384953	2009
18	Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. ⁵³ ⁶²	Sun Y...Waalkes MP	19524636	2009
19	DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. ⁵³ ⁶²	Ziv O...Livneh Z	19564618	2009
20	Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. ⁵³ ⁶²	Council ML...Bowcock AM	19320745	2009
21	Identification and functional analysis of novel variants of the human melanocortin 1 receptor found in melanoma patients. ⁵³ ⁶²	Perez Oliva AB...Ribas G	19338054	2009
22	c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. ⁵³ ⁶²	Choi HS...Dong Z	19204086	2009
23	p53 protein expression in skin with different levels of photoaging. ⁵³ ⁶²	de Castro IA...Bakos L	19292788	2009
24	Vitamin D and skin cancer: a meta-analysis. ⁵³ ⁶²	Gandini S...Testori A	19008093	2009
25	The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. ⁵³ ⁶²	Brudnik U...Kanas P	18637131	2009
26	Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. ⁵³ ⁶²	Evke E...Kahveci Z	19096907	2009
27	Differential activity of UV-DDB in mouse keratinocytes and fibroblasts: impact on DNA repair and UV-induced skin cancer. ⁵³ ⁶²	Pines A...Mullenders LH	18996499	2009
28	The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. ⁵³ ⁶²	Sakiz D...Kabukcuoglu F	19577853	2009
29	Comparative study of nucleotide excision repair defects between XPD-mutated fibroblasts derived from trichothiodystrophy and xeroderma pigmentosum patients. ⁵³ ⁶²	Nishiwaki T...Mori T	18817897	2008
30	Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene. ⁵³ ⁶²	Miccadei S...Civitareale D	19017395	2008
31	Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy. ⁵³ ⁶²	Boyle J...Kraemer KH	18470933	2008
32	Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. ⁵³ ⁶²	Bikle DD	18787544	2008
33	A novel AKT3 mutation in melanoma tumours and cell lines. ⁵³ ⁶²	Davies MA...Mills GB	18813315	2008
34	Prenatal manifestation in a family affected by nevoid basal cell carcinoma syndrome. ⁵³ ⁶²	Le Brun Keris Y...Lespinasse J	18539553	2008
35	Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. ⁵³ ⁶²	Gueranger Q...Weill JC	18586118	2008
36	Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. ⁵³ ⁶²	Carless MA...Griffiths LR	18647306	2008
37	Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. ⁵³ ⁶²	Frechet M...Magnaldo T	18469853	2008
38	Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. ⁵³ ⁶²	Nan H...Han J	18510673	2008
39	Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation. ⁵³ ⁶²	Fei JW...de Villiers EM	18412244	2008
40	p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. ⁵³ ⁶²	Lassacher A...Wolf P	18219279	2008
41	FLIP ing the coin? Death receptor-mediated signals during skin tumorigenesis. ⁵³ ⁶²	Leverkus M...Geserick P	18558995	2008
42	Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. ⁵³ ⁶²	Smith AG...Muscat GE	18292087	2008
43	Melanocytes expressing MC1R polymorphisms associated with red hair color have altered MSH-ligand activated pigmentary responses in coculture with keratinocytes. ⁵³ ⁶²	Roberts DW...Sturm RA	17960564	2008
44	Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. ⁵³ ⁶²	Paolino D...Fresta M	18191509	2008
45	MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. ⁵³ ⁶²	Scherer D...Kumar R	18067130	2008
46	Nucleotide diversity and population differentiation of the melanocortin 1 receptor gene, MC1R. ⁵³ ⁶²	Savage SA...Landi MT	18402696	2008
47	Comparison of induced and cancer-associated mutational spectra using multivariate data analysis. ⁵³ ⁶²	Lewis PD...Burns PA	18296683	2008
48	Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. ⁵³ ⁶²	Rundhaug JE...Fischer SM	18194346	2008
49	The melanocortin 1 receptor and the UV response of human melanocytes--a shift in paradigm. ⁵³ ⁶²	Abdel-Malek ZA...Starner R	18282187	2008
50	Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). ⁵³ ⁶²	Geary J...Hodgson SV	17939062	2008

Sources

Genes for Skin Carcinoma

Genes related to Skin Carcinoma (0 elite genes):

(show top 50) (show all 83)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	32.03	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11429426 8625503 10190297 (more) 17270229 9732059 12635827 8994835 8068178 10362120 10749125 18060027 15145527 8755585 12619107 9821074 9383997 8664219 14971643 8437842 8176007 11552722 12444960 7767977 19292788 16251483 11078762 8221675 18510673 17021352 9349508 12538356 15752287 9184777 8300928 8336934 15447725 9473769 11152598 10719058 7473071 12190879 7997263 10940505 11220671 12700123 7722037 7923098 18296683 17469758 15748640 15748639 15010313 12903851 12859744 10223623 10537000 9204056 9183379 8151121 15748635 15230885 12619109 9137102 17409394 9343491 12444958 10612830 10508168 9095000 8707401 7769260 9445187 19577853 18191509 18412244 9261472 11720736 10764991 19096907 18219279 16739124 12239425 11376686 9242514 7597286 8030743 8128225 8278394 1793482 20129038 18060030 12359052 11407932 11702610 10523843 10517972 9635858 17403527 12950498
2	TMC8	Transmembrane Channel Like 8	Protein Coding	29.28	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	12812529
3	TMC6	Transmembrane Channel Like 6	Protein Coding	28.15	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	12812529
4	PTCH1	Patched 1	Protein Coding	25.4	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	2297704 10838143 18539553 (more) 10537000 10545995 17988327 10517972
5	MC1R	Melanocortin 1 Receptor	Protein Coding	24.96	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	16721784 12753400 17130136 (more) 12006619 17222061 19452503 17279550 11830546 10537004 18539553 19384953 10340440 15250941 18282187 11254446 20381640 17960564 20129839 15650023 15372380 19017395 18510673 16962028 18292087 10885670 20066389 18637131 17916200 18067130 15748644 15533235 12394181 18402696 11487574 20126537 19338054 17616515 12950734 14961558
6	XPA	XPA, DNA Damage Recognition And Repair Factor	Protein Coding	22.45	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	16905156 9415314 12509227 (more) 10602497 7614689
7	CDK4	Cyclin Dependent Kinase 4	Protein Coding	22.41	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	11078762 12470986
8	ERCC2	ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit	Protein Coding	21.95	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	15941969 9192652 11606376 (more) 18817897 15598761 10416615 18470933 10753184
9	POLH	DNA Polymerase Eta	Protein Coding	20.6	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	12967656 10801132 12546696 (more) 16823845 20008555 17334634 19564618 10932195 11113111
10	DDB2	Damage Specific DNA Binding Protein 2	Protein Coding	19.64	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	18996499 12509284
11	ERCC3	ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit	Protein Coding	19.35	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	18470933 18817897
12	H2AC18	H2A Clustered Histone 18	Protein Coding	19.14	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
13	TYR	Tyrosinase	Protein Coding	18.86	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19320745
14	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	18.76	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
15	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	18.66	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
16	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	18.6	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	9485025 10882869 15018897 (more) 9472093 9334204 10602506
17	MIR21	MicroRNA 21	RNA Gene	18.4	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
18	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	18.22	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	17645375 16921490 9635856 (more) 12164941 16778813 20096264 10678579 12370831 12847753 14499495 15018897 15491425 10417761 11090967 11162632 11439356 14502644 15492414 20399617 12202973 11401676 16185283 17488409 15619216 18194346
19	ERCC6	ERCC Excision Repair 6, Chromatin Remodeling Factor	Protein Coding	18.07	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
20	CASP3	Caspase 3	Protein Coding	17.53	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19204086
21	IL7	Interleukin 7	Protein Coding	17.32	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders (show sections)
22	THBS1	Thrombospondin 1	Protein Coding	17.24	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	9833775 10051595 9365532
23	ASIP	Agouti Signaling Protein	Protein Coding	16.94	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19384953
24	KRT8	Keratin 8	Protein Coding	16.77	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	7508123
25	MSH2	MutS Homolog 2	Protein Coding	16.59	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19818066 17939062
26	GLI1	GLI Family Zinc Finger 1	Protein Coding	16.37	DISEASES inferred ¹⁴ ¹⁴
27	TYRP1	Tyrosinase Related Protein 1	Protein Coding	16.24	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19384953 15707965
28	SHH	Sonic Hedgehog Signaling Molecule	Protein Coding	16.01	DISEASES inferred ¹⁴ ¹⁴
29	AKT3	AKT Serine/Threonine Kinase 3	Protein Coding	15.97	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	18813315
30	CD274	CD274 Molecule	Protein Coding	15.79	DISEASES inferred ¹⁴ ¹⁴
31	GLI2	GLI Family Zinc Finger 2	Protein Coding	15.69	DISEASES inferred ¹⁴ ¹⁴
32	VDR	Vitamin D Receptor	Protein Coding	15.68	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	16950800 18647306 19667145 (more) 18787544 16039846 19008093 17627246
33	ODC1	Ornithine Decarboxylase 1	Protein Coding	15.57	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	15748645
34	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	15.43	DISEASES inferred ¹⁴ ¹⁴
35	MIR199A1	MicroRNA 199a-1	RNA Gene	15.42	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
36	MIR31	MicroRNA 31	RNA Gene	15.38	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
37	MIR18A	MicroRNA 18a	RNA Gene	15.33	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
38	MIR140	MicroRNA 140	RNA Gene	15.32	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
39	MIR455	MicroRNA 455	RNA Gene	15.31	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
40	MIR30A	MicroRNA 30a	RNA Gene	15.22	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
41	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	15.18	DISEASES inferred ¹⁴ ¹⁴
42	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	15.18	DISEASES inferred ¹⁴ ¹⁴
43	XRCC3	X-Ray Repair Cross Complementing 3	Protein Coding	15.17	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	15126335 16791138
44	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	15.11	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	15018897 11439356 10602506 (more) 7478512
45	KRT20	Keratin 20	Protein Coding	15.07	DISEASES inferred ¹⁴ ¹⁴
46	SUFU	SUFU Negative Regulator Of Hedgehog Signaling	Protein Coding	15.06	DISEASES inferred ¹⁴ ¹⁴
47	RHOH	Ras Homolog Family Member H	Protein Coding	15	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders (show sections)
48	CD8A	CD8a Molecule	Protein Coding	14.98	DISEASES inferred ¹⁴ ¹⁴
49	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	14.92	DISEASES inferred ¹⁴ ¹⁴
50	XPC	XPC Complex Subunit, DNA Damage Recognition And Repair Factor	Protein Coding	14.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8994835 10749125 11376686 (more) 15863269 10604143 12509261 11511294 18469853 12173040 10602497 15010313 9415314

Sources

Variations for Skin Carcinoma

Cosmic variations for Skin Carcinoma:

⁸ (show top 50) (show all 2121)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM144653327	TP53	skin,face,carcinoma,NS	c.*131C>T	p.?	17:7670685-7670685	18
2	COSM112254631	TP53	skin,face,carcinoma,squamous cell carcinoma	c.586C>T	p.R196*	17:7674945-7674945	18
3	COSM143371865	TP53	skin,face,carcinoma,NS	c.469C>T	p.R157*	17:7674945-7674945	18
4	COSM93183824	TP53	skin,face,carcinoma,NS	c.680C>T	p.S227F	17:7674283-7674283	18
5	COSM143943797	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	18
6	COSM121875437	TP53	skin,face,carcinoma,squamous cell carcinoma	c.178C>T	p.Q60*	17:7674957-7674957	18
7	COSM143388508	TP53	skin,face,carcinoma,squamous cell carcinoma	c.629G>C	p.R210T	17:7674217-7674217	18
8	COSM111758868	TP53	skin,face,carcinoma,squamous cell carcinoma	c.742C>T	p.R248W	17:7674221-7674221	18
9	COSM142570304	TP53	skin,face,carcinoma,NS	c.715C>T	p.P239S	17:7673788-7673788	18
10	COSM142560384	TP53	skin,face,carcinoma,squamous cell carcinoma	c.616G>T	p.G206C	17:7674230-7674230	18
11	COSM142742951	TP53	skin,face,carcinoma,NS	c.315G>A	p.Q105=	17:7675180-7675180	18
12	COSM105639284	TP53	skin,face,carcinoma,NS	c.712T>A	p.C238S	17:7674251-7674251	18
13	COSM112253879	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	18
14	COSM121878773	TP53	skin,face,carcinoma,NS	c.241C>T	p.R81*	17:7674894-7674894	18
15	COSM111776406	TP53	skin,face,carcinoma,NS	c.993+1G>A	p.?	17:7673534-7673534	18
16	COSM142837551	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	18
17	COSM122742188	TP53	skin,face,carcinoma,NS	c.58C>T	p.P20S	17:7675158-7675158	18
18	COSM122735020	TP53	skin,face,carcinoma,NS	c.190C>T	p.R64*	17:7674945-7674945	18
19	COSM144028845	TP53	skin,face,carcinoma,NS	c.679T>A	p.C227S	17:7674251-7674251	18
20	COSM144021997	TP53	skin,face,carcinoma,squamous cell carcinoma	c.421C>T	p.P141S	17:7675158-7675158	18
21	COSM144015364	TP53	skin,face,carcinoma,NS	c.604C>T	p.R202*	17:7674894-7674894	18
22	COSM121877621	TP53	skin,face,carcinoma,NS	c.190C>T	p.R64*	17:7674945-7674945	18
23	COSM93201188	TP53	skin,face,carcinoma,NS	c.993+1G>A	p.?	17:7673534-7673534	18
24	COSM144658487	TP53	skin,face,carcinoma,squamous cell carcinoma	c.143C>A	p.P48Q	17:7676109-7676109	18
25	COSM142639459	TP53	skin,face,carcinoma,squamous cell carcinoma	c.597T>A	p.C199*	17:7674249-7674249	18
26	COSM105620390	TP53	skin,face,carcinoma,squamous cell carcinoma	c.733G>T	p.G245C	17:7674230-7674230	18
27	COSM144014436	TP53	skin,face,carcinoma,NS	c.553C>T	p.R185*	17:7674945-7674945	18
28	COSM112253194	TP53	skin,face,carcinoma,NS	c.833C>G	p.P278R	17:7673787-7673787	18
29	COSM112263720	TP53	skin,face,carcinoma,squamous cell carcinoma	c.832C>T	p.P278S	17:7673788-7673788	18
30	COSM122272676	TP53	skin,face,carcinoma,NS	c.190C>T	p.R64*	17:7674945-7674945	18
31	COSM93239210	TP53	skin,face,carcinoma,squamous cell carcinoma	c.706T>C	p.Y236H	17:7674257-7674257	18
32	COSM144651436	TP53	skin,face,carcinoma,NS	c.625C>T	p.R209W	17:7674221-7674221	18
33	COSM105620642	TP53	skin,face,carcinoma,squamous cell carcinoma	c.742C>T	p.R248W	17:7674221-7674221	18
34	COSM144013959	TP53	skin,face,carcinoma,NS	c.502C>T	p.H168Y	17:7675077-7675077	18
35	COSM143949062	TP53	skin,face,carcinoma,squamous cell carcinoma	c.263A>C	p.N88T	17:7674223-7674223	18
36	COSM121876459	TP53	skin,face,carcinoma,NS	c.346C>T	p.R116W	17:7674221-7674221	18
37	COSM111775215	TP53	skin,face,carcinoma,squamous cell carcinoma	c.746G>C	p.R249T	17:7674217-7674217	18
38	COSM111765498	TP53	skin,face,carcinoma,NS	c.854A>T	p.E285V	17:7673766-7673766	18
39	COSM142838765	TP53	skin,face,carcinoma,NS	c.*131C>T	p.?	17:7670685-7670685	18
40	COSM93191278	TP53	skin,face,carcinoma,NS	c.517G>A	p.V173M	17:7675095-7675095	18
41	COSM144129318	TP53	skin,face,carcinoma,squamous cell carcinoma	c.229T>C	p.Y77H	17:7674257-7674257	18
42	COSM144088618	TP53	skin,face,carcinoma,squamous cell carcinoma	c.160C>T	p.R54*	17:7674894-7674894	18
43	COSM87910628	TP53	skin,face,carcinoma,squamous cell carcinoma	c.772G>A	p.E258K	17:7674191-7674191	18
44	COSM87898709	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	18
45	COSM144691571	TP53	skin,face,carcinoma,NS	c.302C>T	p.T101I	17:7675193-7675193	18
46	COSM144013187	TP53	skin,face,carcinoma,NS	c.800C>G	p.P267R	17:7673787-7673787	18
47	COSM143156943	TP53	skin,face,carcinoma,NS	c.203C>T	p.S68F	17:7674283-7674283	18
48	COSM144324830	TP53	skin,face,carcinoma,NS	c.595T>A	p.C199S	17:7674251-7674251	18
49	COSM144662686	TP53	skin,face,carcinoma,squamous cell carcinoma	c.715C>T	p.P239S	17:7673788-7673788	18
50	COSM144650676	TP53	skin,face,carcinoma,squamous cell carcinoma	c.457C>T	p.Q153*	17:7674957-7674957	18

Sources

Expression for Skin Carcinoma

Search GEO for disease gene expression data for Skin Carcinoma.

Sources

Pathways for Skin Carcinoma

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Homology Directed Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex ⁶⁶ DNA Double-Strand Break Repair ⁶⁶ DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Processing of DNA double-strand break ends ⁶⁶	13.05	XPA TP53 POLH H2AC18 ERCC6 ERCC3
2	Transcription-Coupled Nucleotide Excision Repair (TC-NER) ⁶⁶ Show member pathways DNA Damage Recognition in GG-NER ⁶⁶ Dual incision in TC-NER ⁶⁶ Formation of Incision Complex in GG-NER ⁶⁶ Formation of TC-NER Pre-Incision Complex ⁶⁶ Gap-filling DNA repair synthesis and ligation in TC-NER ⁶⁶ Global Genome Nucleotide Excision Repair (GG-NER) ⁶⁶ Nucleotide Excision Repair ⁶⁶	12.74	XPA ERCC6 ERCC3 ERCC2 DDB2
3	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.72	TP53 JUN DDB2 CDK4 CASP3
4	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.57	CASP3 CDK4 DDB2 JUN PTGS2 TP53
5	DNA repair pathways, full network ⁷⁴ Show member pathways Defective Mismatch Repair Associated With MSH2 ⁶⁶ Defective Mismatch Repair Associated With MSH3 ⁶⁶ Defective Mismatch Repair Associated With MSH6 ⁶⁶ Diseases of Mismatch Repair (MMR) ⁶⁶ Dual Incision in GG-NER ⁶⁶ Homologous recombination ⁷⁴ Mismatch Repair ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) ⁶⁶ Non-homologous end joining ⁷⁴ Nucleotide excision repair ⁷⁴ Nucleotide excision repair in xeroderma pigmentosum ⁷⁴ Nucleotide Excision Repair Pathway ⁶⁴	12.44	XPA POLH ERCC6 ERCC3 ERCC2 DDB2
6	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.36	TP53 PTGS2 JUN CASP3
7	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.35	TP53 JUN DDB2 CDK4
8	WNT Signaling ⁶⁴	12.33	TP53 PTGS2 JUN CDK4
9	DNA Damage ³	12.17	XPA TP53 POLH ERCC3 ERCC2 DDB2
10	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.09	XPA TP53 POLH ERCC6 ERCC3 ERCC2
11	Integrated breast cancer pathway ⁷⁴	12.04	TP53 JUN CDK4 CASP3
12	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12	TP53 DDB2 CDK4 CASP3
13	Spinal cord injury ⁷⁴	11.86	TP53 PTGS2 CDK4 CASP3
14	RNA Polymerase I Transcription Termination ⁶⁶ Show member pathways Assembly of RNA Polymerase-I Initiation Complex ⁶⁴ RNA Polymerase I Transcription Initiation ⁶⁶	11.74	ERCC6 ERCC3 ERCC2
15	Small cell lung cancer ⁷⁴	11.64	TP53 PTGS2 DDB2 CDK4 CASP3
16	DYRK1A ⁷⁴	11.56	TP53 CDK4 CASP3
17	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.56	PTGS2 JUN CDK4 CASP3
18	Prader-Willi and Angelman syndrome ⁷⁴	11.54	CDK4 TP53 TYR
19	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.52	TP53 JUN CASP3
20	Transcription_P53 signaling pathway ²²	11.5	XPA TP53 JUN ERCC3 ERCC2
21	Netrin-UNC5B signaling pathway ⁷⁴	11.46	TP53 JUN CASP3
22	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.36	CASP3 JUN PTGS2 TP53
23	Integrated cancer pathway ⁷⁴	11.29	TP53 CDK4 CASP3
24	Signaling mediated by p38-alpha and p38-beta ⁶¹	11.22	TP53 PTGS2 JUN
25	miRNA regulation of p53 pathway in prostate cancer ⁷⁴	11.19	TP53 DDB2 CASP3
26	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.48	XPA POLH ERCC6 ERCC3 ERCC2

Sources

GO Terms for Skin Carcinoma

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of apoptotic process	GO:0043065	10.25	TP53 PTGS2 MIR21 JUN ERCC3 CASP3
2	DNA repair	GO:0006281	10.24	XPA POLH ERCC6 ERCC3 ERCC2 DDB2
3	response to xenobiotic stimulus	GO:0009410	10.22	TP53 PTGS2 PTCH1 JUN CDK4 CASP3
4	response to oxidative stress	GO:0006979	10.11	ERCC2 ERCC3 ERCC6 PTGS2 TP53
5	cellular response to DNA damage stimulus	GO:0006974	10.11	XPA TP53 POLH ERCC6 ERCC3 ERCC2
6	embryonic organ development	GO:0048568	10.03	TP53 PTCH1 ERCC3
7	response to X-ray	GO:0010165	10	CASP3 ERCC6 TP53
8	UV-damage excision repair	GO:0070914	9.91	XPA MC1R DDB2
9	transcription-coupled nucleotide-excision repair	GO:0006283	9.88	ERCC6 ERCC3 ERCC2
10	cellular response to UV-C	GO:0071494	9.87	TP53 POLH
11	transcription elongation by RNA polymerase I	GO:0006362	9.85	ERCC6 ERCC2
12	nucleotide-excision repair	GO:0006289	9.81	XPA TP53 ERCC3 ERCC2 DDB2
13	pyrimidine dimer repair	GO:0006290	9.8	DDB2 ERCC6 POLH
14	nucleotide-excision repair, DNA duplex unwinding	GO:0000717	9.67	ERCC3 ERCC2
15	obsolete nucleotide-excision repair, DNA incision	GO:0033683	9.56	XPA ERCC3 ERCC2
16	UV protection	GO:0009650	9.56	XPA MC1R ERCC3 ERCC2
17	response to UV	GO:0009411	9.4	TYR TP53 ERCC6 ERCC3 ERCC2 DDB2

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein N-terminus binding	GO:0047485	9.56	TP53 ERCC6 ERCC3 ERCC2
2	DNA helicase activity	GO:0003678	9.46	ERCC6 ERCC3 ERCC2
3	damaged DNA binding	GO:0003684	9.32	XPA POLH ERCC3 ERCC2 DDB2